Autolus Therapeutics (AUTL) Current Deferred Revenue (2021 - 2025)

Autolus Therapeutics (AUTL) has 5 years of Current Deferred Revenue data on file, last reported at $7.6 million in Q3 2025.

• For the quarter ending Q3 2025, Current Deferred Revenue fell 96.26% year-over-year to $7.6 million; the trailing twelve-month figure through Sep 2025 stood at $7.6 million (down 96.26% YoY), and the FY2022 full-year result was $35.0 million, down 25.53% from the prior year.
• Current Deferred Revenue for Q3 2025 stood at $7.6 million, up from $2.1 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $203.4 million in Q3 2024 and bottomed at $2.1 million in Q2 2025.
• The 5-year median for Current Deferred Revenue is $47.0 million (2021), against an average of $91.7 million.
• The widest annual swing landed in 2024, when Current Deferred Revenue soared 44.46%; it then sank 98.93% in 2025.
• A 5-year view of Current Deferred Revenue shows it stood at $47.0 million in 2021, then dropped by 25.53% to $35.0 million in 2022, then soared by 302.29% to $140.8 million in 2023, then jumped by 44.46% to $203.4 million in 2024, then slumped by 96.26% to $7.6 million in 2025.
• The last three Current Deferred Revenue figures came in at $7.6 million (Q3 2025), $2.1 million (Q2 2025), and $4.7 million (Q1 2025), per Business Quant data.

Peer Comparison